Metolazone
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Metolazone
- Metolazone: From an Undocumented Original Indication to Malignant Hypertensive Renal Disease
Metolazone: From an Undocumented Original Indication to Malignant Hypertensive Renal Disease
One-Sentence Summary
The evidence pack does not contain metolazone's original approved indication (no New Zealand license records and no logged original indication text), so its established clinical use cannot be confirmed from this data source. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license records or original indication data in this evidence pack) |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| New Zealand Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the repurposing rationale supplied alongside the prediction, metolazone is a thiazide-like diuretic that acts on the distal convoluted tubule to inhibit Na-Cl reabsorption — a mechanism theoretically linked to volume control in hypertension and renal hypertension.
However, malignant hypertension is a hypertensive emergency typically managed with intravenous antihypertensives, not oral diuretics, so the mechanistic fit is indirect at best. No clinical trials or published literature currently connect metolazone to this indication — the entire prediction rests on the TxGNN embedding score, without any corroborating clinical or mechanistic evidence to strengthen the case.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Metolazone is not currently marketed in New Zealand, and no product authorizations are recorded in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA package insert warnings/contraindications are flagged in this evidence pack as a Blocking data gap — this must be resolved before any further safety assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is supported by TxGNN score alone (L5), with no clinical trials, no literature, and unconfirmed mechanism of action — insufficient evidence to advance, and malignant hypertension's status as an acute emergency further weakens the fit with an oral diuretic.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — currently blocking
- Confirmed mechanism of action data from DrugBank or primary literature
- Any preclinical or observational evidence linking metolazone to malignant hypertensive renal disease
- Confirmation of metolazone's original approved indication and market history, since this evidence pack currently has none on record
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.